41 results match your criteria: "Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases[Affiliation]"
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.
Ther Adv Neurol Disord
November 2024
Department of Neuroscience, Central Clinical School, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia.
Background: The relationship between coronavirus disease 2019 (COVID-19) infection and multiple sclerosis (MS) relapse and disease progression remains unclear. Previous studies are limited by small sample sizes and most lack a propensity-matched control cohort.
Objective: To evaluate the effect of COVID-19 infection on MS disease course with a large propensity-matched cohort.
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Neurol Neuroimmunol Neuroinflamm
November 2024
From the Department of Neuroscience (W.Z.Y., A.V.D.W., H.B., V.G.J.), School of Translational Medicine, Monash University; Department of Neurology (W.Z.Y., A.V.D.W., O.G.S., H.B., V.G.J.), Alfred Health, Melbourne; Department of Neurology (O.G.S., K.B.), Box Hill Hospital; Department of Neurosciences (O.G.S., K.B.), Eastern Health Clinical School, Monash University, Box Hill; Neuroimmunology Centre (T.K.), Department of Neurology, Royal Melbourne Hospital; CORe (T.K.), Department of Medicine, University of Melbourne, Australia; Amiri Hospital (R.A.), Sharq, Kuwait; Perron Institute for Neurological and Translational Science (A.G.K., M.J.F.-P., W.M.C.), University of Western Australia, Nedlands; Centre for Molecular Medicine and Innovative Therapeutics (A.G.K., M.J.F.-P.), Murdoch University, Perth; Sir Charles Gairdner Hospital (A.G.K., W.M.C.), QEIIMC, Nedlands; University of Newcastle (J.L.-S.), Newcastle; Hunter New England Health (J.L.-S.), John Hunter Hospital, New South Wales, Australia; Karadeniz Technical University (C.B.), Medical Faculty, Trabzon; Izmir University of Economics (S.O.), Medical Point Hospital, Izmir, Turkey; University Hospital Center Zagreb (M.H.); University of Zagreb (M.H.), School of Medicine, Croatia; Monash Health (N.A.J.); Department of Medicine (N.A.J.), School of Clinical Sciences, Monash University, Melbourne, Australia; CHUM and Universite de Montreal (A.P., M.G., P.D.), Canada; Neurology Department (S.M.B.), Faculty of Medicine, Mazandaran University of Medical Sciences, Iran; University of New South Wales (Suzanne Hodgkinson), Sydney, Australia; Cliniques Universitaires Saint-Luc (V.V.P.), Brussels; Université Catholique de Louvain (V.V.P.); Universitary Hospital Ghent (G.L.); Department of Neurology (B.W.), Antwerp University Hospital, Edegem; Translational Neurosciences Research Group (B.W.), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; CSSS Saint-Jérôme (J.P.), Saint-Jerome, Canada; Department of Neuroscience (M.F.), Neurology Unit-MS Center, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy; Department of Biotechnological and Applied Clinical Sciences (M.F.), University of L'Aquila, Italy; Groene Hart Ziekenhuis (K.D.G.), Gouda, Netherlands; Charles University in Prague and General University Hospital (D.H., E.K.H.), Prague, Czech Republic; Yeditepe University Kosuyolu Hospital (R.K.), Neurological Sciences, Istanbul, Turkey; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Catania; UOS Sclerosi Multipla (F.P.), AOU Policlinico "G Rodloico-San Marco", University of Catania, Italy; University of Queensland (P.A.M.), Brisbane; Royal Brisbane and Women's Hospital (P.A.M.), Australia; Centro Sclerosi Multipla (D.M.), UOC Neurologia, Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania, Italy; Koc University (A.A.), Istanbul, Turkey; Nemocnice Jihlava (Radek Ampapa), Jihlava, Czech Republic; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino (D.S.), Avellino, Italy; Zuyderland Medical Center (O.H.H.G.), Sittard-Geleen; School for Mental Health and Neuroscience (O.H.H.G.), Maastricht University, The Netherlands; Centro Hospitalar Universitario de Sao Joao (M.J.S.); Faculty of Health Sciences (M.J.S.), University Fernando Pessoa, Porto, Portugal; Royal Victoria Hospital (Stella Hughes), Belfast, United Kingdom; Department of Neurology (R.G., S.M.), Research laboratory LR18SP03, Clinical investigation Center Neurosciences and Mental Health, Razi Hospital; Faculty of Medicine of Tunis (R.G., S.M.), University of Tunis El Manar, Tunis, Tunisia; Austin Health (R.A.M.), Melbourne, Australia; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Azienda Sanitaria Unica Regionale Marche - AV3 (E.C.), Macerata, Italy; Sultan Qaboos University (A.A.-A.), Al-Khodh, Oman; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; St. Michael's Hospital (J.O.), Toronto, Canada; and F. Hoffmann-La Roche Ltd (E.M.-L.R., S.G., N.P.), Basel, Switzerland.
Background And Objectives: Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS disease activity. Data remain limited regarding use of disease-modifying therapies (DMTs), including OCR, and disease activity during peripregnancy periods.
View Article and Find Full Text PDFPredictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
J Neurol Neurosurg Psychiatry
September 2024
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia
Background: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD.
View Article and Find Full Text PDFEffectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Mult Scler
August 2024
CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking.
Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS.
Methods: Patients with relapsing-remitting MS treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab were identified in the global MSBase cohort and two additional UK centres.
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.
PLOS Digit Health
July 2024
Data Science Institute, Hasselt University, Belgium.
Article Synopsis
- * Machine learning models were applied to predict confirmed disability progression after two years, achieving a ROC-AUC score of 0.71, indicating moderate accuracy, while historical disability was found to be a stronger predictor than treatment or relapse history.
- * The research followed strict guidelines and made its coding accessible for others to facilitate future benchmarking in predicting disability progression in MS patients.
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
J Neurol
September 2024
Department of Neuroscience, Central Clinical School, The Alfred, Melbourne, VIC, Australia.
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.
Methods: A multi-centre longitudinal study with 8,771 participants from MSBase was conducted.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
J Neurol Neurosurg Psychiatry
October 2024
University Hospital Ghent, Gent, Belgium.
Background: It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course.
Methods: This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in the first 2 years after diagnosis (ARR2) were assessed using (cox) regression analysis.
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Front Neurol
December 2023
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Article Synopsis
- The study aims to identify predictors of treatment switching in patients with relapsing-remitting MS using data from multiple national registries.
- A total of 269,822 treatment episodes from 110,326 patients were analyzed, focusing on those who started disease-modifying treatments during their RRMS phase.
- Key findings indicate that higher disability scores (EDSS), being female, and older age increase the likelihood of treatment switching, with certain DMTs initiated between 2007 and 2012 showing even higher rates of switching.
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
J Med Econ
December 2023
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
Aim: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis (RES-RRMS).
Methods: Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD). Matched cohorts were selected by 3-way multinomial propensity score matching, and the annualized relapse rate (ARR) and 6-month-confirmed disability worsening (CDW6M) and improvement (CDI6M) were compared between treatment groups.
Risk of secondary progressive multiple sclerosis after early worsening of disability.
J Neurol Neurosurg Psychiatry
December 2023
Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Background: Whether progression independent of relapse activity (PIRA) heralds earlier onset of secondary progressive multiple sclerosis (SPMS) and more rapid accumulation of disability during SPMS remains to be determined. We investigated the association between early PIRA, relapse-associated worsening (RAW) of disability and time to SPMS, subsequent disability progression and their response to therapy.
Methods: This observational cohort study included patients with relapsing-remitting multiple sclerosis (RRMS) from the MSBase international registry across 146 centres and 39 countries.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
November 2023
CORe, Department of Medicine, University of Melbourne, Melbourne 3050, Australia.
Article Synopsis
- The study investigates geographical differences in the risk of secondary progressive multiple sclerosis (SPMS) and how these may be influenced by factors like latitude and treatment types.
- It utilizes data from a global patient registry, focusing on relapsing-remitting multiple sclerosis patients and factors such as age, sex, and treatment efficacy.
- The research analyzes data from over 51,000 patients across 27 countries to establish patterns in the progression from relapsing-remitting to secondary progressive phases of the disease.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
JAMA Neurol
August 2023
Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Article Synopsis
- Ocrelizumab, a targeted monoclonal antibody for treating relapsing-remitting MS, significantly reduces relapse rates and disability compared to interferon beta 1a, while rituximab is often used off-label as an alternative.
- This study aimed to determine if rituximab's effectiveness is comparable (noninferior) to that of ocrelizumab in treating relapsing-remitting MS.
- The observational study included over 1600 patients from MS registries with matched baseline characteristics, focusing on annual relapse rates as the primary outcome measure.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler
June 2023
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear.
Objective: To determine whether early non-disabling relapses predict disability accumulation in RRMS.
Methods: We redefined mild relapses in MSBase as 'non-disabling', and moderate or severe relapses as 'disabling'.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
March 2023
CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia/Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Background: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Among the used techniques to reduce indication bias are propensity score matching and marginal structural models.
View Article and Find Full Text PDFVariability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
April 2023
Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia.
Background And Purpose: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS).
Methods: We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year.
Background: Fingolimod, natalizumab, and ocrelizumab are commonly used in the second-line treatment of relapsing-remitting multiple sclerosis (RRMS). However, these have only been compared in observational studies, not in controlled trials, with limited and inconclusive results being reported. A comparison of their effect on relapse and disability in a real-world setting is therefore needed.
View Article and Find Full Text PDFExternal validation of a clinical prediction model in multiple sclerosis.
Mult Scler
February 2023
Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Parkville, VIC, Australia/MS Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Article Synopsis
- Timely initiation of disease modifying therapy (DMT) is essential for effective management of multiple sclerosis (MS).
- The study aimed to validate a predictive model for individual treatment responses using data from patients in the Middle East who were not part of the initial model development.
- The results showed the model had high accuracy (81%-96%) in predicting disability changes, moderate accuracy (73%-91%) for relapses, but lower accuracy (<44%) for treatment discontinuation and variable accuracy (50%-98%) for conversion to secondary progressive MS, indicating its broader applicability across different populations.
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Mult Scler
February 2023
MSBase Foundation, Melbourne, VIC, Australia/Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Background: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was established in clinical trials and confirmed with real-world experience.
Objectives: Use real-world data to compare treatment patterns and clinical outcomes in people with MS (pwMS) treated with cladribine tablets versus other oral DMTs.
Methods: Retrospective treatment comparisons were based on data from the international MSBase registry.
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
J Neurol Neurosurg Psychiatry
September 2022
CORe, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Background: Early recognition of markers of faster disability worsening in paediatric-onset multiple sclerosis (MS) is a key requisite of personalised therapy for children with MS at the earliest possible time.
Objective: To identify early predictors of rapid disability accrual in patients with paediatric-onset MS.
Methods: Using the global MSBase registry, we identified patients who were <18 years old at the onset of MS symptoms.
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Neurology
October 2022
From the CORe (I.R., C.M., T.K.), Department of Medicine, University of Melbourne, Australia; Melbourne MS Centre (I.R., C.M., T.K.), Department of Neurology, Royal Melbourne Hospital, Australia; Rennes, University (E.L.), EHESP, REPERES EA 7449, France; Univ Rennes (E.L.), CHU Rennes, Inserm, CIC 1414 ([Centre d'Investigation Clinique de Rennes]), France; Université de Lyon (R.C.), Université Claude Bernard Lyon 1, France; Hospices Civils de Lyon (R.C.), Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Bron, France; Observatoire Français de La Sclérose en Plaques (R.C.), Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, France; Eugène Devic EDMUS Foundation Against Multiple Sclerosis (R.C.), State-approved Foundation, Bron, France; Department of Neurology and Center of Clinical Neuroscience (D.H., E.K.H.), First Faculty of Medicine, Charles University in Prague and General University Hospital, Czech Republic; Nancy University Hospital (M.D.), Department of Neurology, Nancy, France; Université de Lorraine (M.D.), APEMAC, Nancy, France; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Catania, Italy; Multiple Sclerosis Center (F.P.), University of Catania, Italy; CHU de Strasbourg (J.D.S.), Department of Neurology and Clinical Investigation Center, CIC 1434, INSERM 1434, Strasbourg, France; Hospital Universitario Virgen Macarena (G.I., S.E.), Sevilla, Spain; CHU Pontchaillou (G.E.), CIC1414 INSERM, Rennes, France; CHUM MS Center and Universite de Montreal (A.P., M.G.), Canada; Dokuz Eylul University (S.O.), Konak/Izmir, Turkey; CISSS Chaudière-Appalache (P.G.), Levis, Canada; CHU Lille (H.Z.), CRCSEP Lille, Univ Lille, U1172, France; CHU de Toulouse (J.C.), Hôpital Pierre-Paul Riquet, Department of Neurology, CRC-SEP, France; Département de Neurologie (E.M.), Hôpital Pitié-Salpêtrière, APHP, Paris; CHU de Dijon (T.M.), Department of Neurology, EA4184, France; Department NEUROFARBA (M.P.A.), University of Florence, Italy; CHU de Montpellier (P.L.), MS Unit, France; University of Montpellier (MUSE) (P.L.), France; Division of Neurology (Raed Alroughani), Department of Medicine, Amiri Hospital, Sharq, Kuwait; Department of Neurology (K.B., O.S.), Box Hill Hospital, Melbourne, Australia; Monash University (K.B., O.S.), Melbourne, Australia; Melbourne MS Centre (K.B.), Royal Melbourne Hospital, Australia; The Alfred Hospital (O.S.), Melbourne, Australia; Medical Faculty (M.T.), 19 Mayis University, Samsun, Turkey; CHU de Nantes (D.A.L.), Service de Neurologie & CIC015 INSERM, France; CRTI-Inserm U1064 (D.A.L.), Nantes, France; CHU de Besançon (E.B.), Service de Neurologie 25 030 Besançon, France; Neuro Rive-Sud (F.G.M.), Quebec, Canada; Neurology (C.L.-F.), UR2CA, Centre Hospitalier Universitaire Pasteur2, Université Nice Côte d'Azur, Nice, France; UOC Neurologia (E.C.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; KTU Medical Faculty Farabi Hospital (C.B.), Trabzon, Turkey; School of Medicine and Public Health (J.L.-S.), University Newcastle, Australia; Department of Neurology (J.L.-S.), John Hunter Hospital, Hunter New England Health, Newcastle, Australia; CHU Clermont-Ferrand (Pierre Clavelou), Department of Neurology; Université Clermont Auvergne, Inserm, Neuro-Dol, Clermont-Ferrand, France; Sorbonne Universités (B.S.), UPMC Paris 06, Brain and Spine Institute, ICM, Hôpital de La Pitié Salpêtrière, Inserm UMR S 1127, CNRS UMR 7225, and Department of Neurology, AP-HP, Saint-Antoine Hospital, Paris, France; CSSS Saint-Jérôme (Julie Prevost), Saint-Jerome, Canada; Neurologic Clinic and Policlinic (L.K.), Departments of Medicine and Clinical Research, University Hospital and University of Basel, Switzerland; Aix Marseille Univ (Jean Pelletier), APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, France; Isfahan University of Medical Sciences (V.S.), Iran; Nehme and Therese Tohme Multiple Sclerosis Center (B.I.Y., S.J.K.), American University of Beirut Medical Center, Beirut, Lebanon; Department of Neurology (Oliver Gerlach), Zuyderland Medical Center, Sittard-Geleen, Netherlands; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino (D.L.A.S.), Italy; Cliniques Universitaires Saint-Luc (V.V.P.), Université Catholique de Louvain, Brussels, Belgium; Fondation Rotschild (Olivier Gout), Department of Neurology, Paris, France; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Hôpital de Poissy (O.H.), Department of Neurology, France; Department of Neurology (E.T.), Nimes University Hospital, France; Institut de Génomique Fonctionnelle (E.T.), UMR5203, INSERM 1191, Univ. Montpellier, France; University of Queensland (P.A.M.), Brisbane, Australia; Royal Brisbane and Women's Hospital (P.A.M.), Australia; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; CHU de Rouen (B.B.), Department of Neurology, France; Flinders University (M.S.), Adelaide, Australia; Instituto de Investigación Sanitaria Biodonostia (T.C.-T.), Hospital Universitario Donostia, San Sebastián, Spain; CHU de Reims (S.B.), Department of Neurology, France; Nemocnice Jihlava (Radek Ampapa), Czech Republic; Monash Medical Centre (E.G.B.), Melbourne, Australia; APHP (A.W.), Hôpital Henri Mondor, Department of Neurology, Créteil, France; Austin Health (R.A.M.), Melbourne, Australia; University Hospital Reina Sofia (E.A.-M.), Cordoba, Spain; CHU de La Martinique (Philippe Cabre), Department of Neurology, Fort-de-France, France; Hôpital Sud Francilien (N.H.B.), Department of Neurology, Corbeil Essonnes, France; Department of Neurology (A.V.W., H.B.), The Alfred Hospital, Melbourne, Australia; Central Clinical School (A.V.W., H.B.), Monash University, Melbourne, Australia; Department of Neurology (G.L., L.V.H.), University Hospital Ghent, Belgium; Hospital Germans Trias I Pujol (C.M.R.-T.), Badalona, Spain; CHU La Milétrie (N.M.), Hôpital Jean Bernard, Department of Neurology, Poitiers, France; Liverpool Hospital (S.H.), Sydney, Australia; Hospital de Galdakao-Usansolo (J.L.S.-M.), Spain; Brain and Mind Centre (M.H.B.), Sydney, Australia; CHU Bicêtre (C.L.), Department of Neurology, F-94275 Le Kremlin Bicêtre, France; Westmead Hospital (Steve Vucic), Sydney, Australia; Department of Neurology (Y.S., R.G.), Razi Hospital, Manouba, Tunisia; Department of Neurology (T.C.), Faculty of Medicine, University of Debrecen, Hungary; Hospital Universitari MútuaTerrassa (J.S.), Barcelona, Spain; Groene Hart Ziekenhuis (K.G.), Gouda, Netherlands; Sultan Qaboos University Hospital (A.A.-A.), Al-Khodh, Oman; Universidade Metropolitana de Santos (Y.D.F.), Santos, Brazil; Service de Neurologie (Sandra Vukusic), Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Centre des Neurosciences de Lyon (Sandra Vukusic), Observatoire Français de La Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, France; and Université Claude Bernard Lyon 1 (Sandra Vukusic), Faculté de Médecine Lyon Est, France.
Article Synopsis
- This study evaluates the rate of disease activity return in multiple sclerosis (MS) patients after they stop using disease-modifying therapy, focusing on relapse rates and factors influencing relapse.
- A large sample of 14,213 patients showed that relapse rates typically increased within 2 months after stopping treatment, with earlier commencement of new therapy reducing these rates significantly.
- Factors predicting relapse included having a higher relapse rate prior to stopping therapy, being younger, being female, and having a higher Expanded Disability Status Scale (EDSS) score, with subsequent therapy reducing both relapse risk and disability progression.
Restless legs syndrome after acute ıschemic stroke and ıts relation to lesion location.
Sleep Biol Rhythms
October 2022
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.
Purpose: We aimed to investigate the prevalence, clinical profiles and lesion location of Restless Legs Syndrome (RLS) developed after ischemic stroke.
Methods: This study prospectively included 244 patients with acute cerebral infarction. All patients were evaluated for RLS, and those who met all of the essential diagnostic criteria of the International RLS Study Group were diagnosed with RLS.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
August 2022
CORe, Department of Medicine, University of Melbourne, Melbourne, Australia.
Article Synopsis
- This study looks at how to predict long-term disability in people with multiple sclerosis (MS) after they show signs of worsening over six months.
- Researchers checked data from thousands of patients to figure out who is more likely to have lasting problems.
- They found that things like age, sex, and how MS affects the person can help tell if someone will continue to get worse, which can help doctors in future treatments.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler
October 2022
Department of Biostatistics, UAB School of Public Health, Birmingham, AL, USA.
Background: The MSBase prediction model of treatment response leverages multiple demographic and clinical characteristics to estimate hazards of relapses, confirmed disability accumulation (CDA), and confirmed disability improvement (CDI). The model did not include Multiple Sclerosis Severity Score (MSSS), a disease duration-adjusted ranked score of disability.
Objective: To incorporate MSSS into the MSBase prediction model and compare model accuracy with and without MSSS.
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180].
Comput Methods Programs Biomed
January 2022
I-Biostat, Data Science Institute, Hasselt University, Diepenbeek, Belgium; Department of Immunology, Biomedical Research Institute, Hasselt University, Diepenbeek 3590, Belgium.
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018.
CNS Drugs
October 2021
Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia.
Background: The multiple sclerosis (MS) landscape has changed over the past two decades across the world and in the Middle East. The Middle East is an ethnically diverse region located between 12° and 42° of latitude and 35° and 54° of longitude and varying altitudes. The magnitude of the shifts observed in the epidemiology and management of MS differ in each region and from country to country.
View Article and Find Full Text PDF